Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

CSPC PHARMACEUTICAL GROUP LIMITED
石藥集團有限公司

(Incorporated in Hong Kong with limited liability)

(Stock Code: 1093)

VOLUNTARY ANNOUNCEMENT

PHASE I CLINICAL TRIAL OF SYS6077 INJECTION FOR THE TREATMENT OF ADVANCED MALIGNANT TUMOURS OFFICIALLY INITIATED AT THE FIRST CENTRE IN CHINA

The Board of Directors (the "**Board**") of CSPC Pharmaceutical Group Limited (the "**Company**", together with its subsidiaries, the "**Group**") is pleased to announce that the Phase I clinical trial (SYS6077–001) of the SYS6077 injection (the "**Product**") developed by the Group for the treatment of advanced malignant tumours has been officially initiated at the first centre in China.

The Product is registered as a Class 1 therapeutic biological product and is a universal off-the-shelf therapeutic messenger ribonucleic acid ("**mRNA**") cancer vaccine developed based on a nano-delivery technology platform. By encoding multiple tumour neoantigens, it activates antigen-specific T-cell immune responses, thereby enhancing the body's ability to recognise and attack tumour cells. Preclinical studies demonstrated that the Product induced specific T-cell immune responses against multiple tumour antigens, and exhibited anti-tumour activity in multiple animal tumour models; compared with other mRNA cancer vaccines, the Product possesses advantages such as broad population coverage, a low risk of immune evasion, and a short preparation cycle.

The Group received the Notice of Approval for Clinical Trial of Drug issued by the National Medical Products Administration of the People's Republic of China in September 2026, and initiated the SYS6077–001 clinical trial upon approval. This approved clinical trial is a multi-centre Phase I clinical trial aimed at evaluating the safety, tolerability, immunogenicity, pharmacokinetic profile, and preliminary anti-tumour activity of the Product at different doses in patients with malignant tumours.

Currently, the recruitment and screening of participants for this clinical trial are actively underway.

By order of the Board
CSPC Pharmaceutical Group Limited
CAI Dong Chen
Chairman

Hong Kong, 28 October 2026

As at the date of this announcement, the Board comprises Mr. CAI Dong Chen, Dr. CAI Lei, Mr. WEI Qingjie, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Dr. LI Chunlei, Dr. YAO Bing, Mr. CAI Xin, Mr. CHEN Weiping, Mr. QU Zhiyong and Mr. ZHANG Yiwei as Executive Directors; and Mr. WANG Bo, Mr. CHEN Chuan, Prof. WANG Hongguang, Mr. AU Chun Kwok Alan, Mr. LAW Cheuk Kin Stephen and Ms. LI Quan as Independent Non-executive Directors.